NIKKEI 225
38,762.17 -160.83 (-0.41%) HANG SENG
18,464.46 +61.46 (+0.33%) CRUDE OIL
73.32 -0.90 (-1.21%) GOLD FUTURES
2,368.60 -0.70 (-0.03%) DOW
38,571.03 -115.27 (-0.30%) Bitcoin GBP
53,889.63 +294.88 (+0.55%)
QIAGEN N.V. (QIA.F)
- Zacks
QIAGEN (QGEN) Advances Precision Medicine With New QIAseq Kit
QIAGEN (QGEN) launches the new QIAseq Multimodal DNA/RNA Lib Kit, facilitating multiomic studies and advancing precision medicine.
- GlobeNewswire
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curvesGermantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal
- Zacks
QIAGEN (QGEN) Develops Test for Research and CDx Application
QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.
